vs

Side-by-side financial comparison of BLACKBAUD INC (BLKB) and Enovis CORP (ENOV). Click either name above to swap in a different company.

Enovis CORP is the larger business by last-quarter revenue ($548.9M vs $295.3M, roughly 1.9× BLACKBAUD INC). BLACKBAUD INC runs the higher net margin — 12.4% vs -104.1%, a 116.5% gap on every dollar of revenue. On growth, Enovis CORP posted the faster year-over-year revenue change (-2.2% vs -2.3%). BLACKBAUD INC produced more free cash flow last quarter ($55.0M vs $29.1M). Over the past eight quarters, Enovis CORP's revenue compounded faster (9.8% CAGR vs 3.0%).

Blackbaud, Inc. is a cloud computing provider that supports nonprofits, foundations, corporations, education institutions, healthcare organizations, religious organizations, and individual change agents. Its products focus on fundraising, website management, CRM, analytics, financial management, ticketing, and education administration.

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.

BLKB vs ENOV — Head-to-Head

Bigger by revenue
ENOV
ENOV
1.9× larger
ENOV
$548.9M
$295.3M
BLKB
Growing faster (revenue YoY)
ENOV
ENOV
+0.1% gap
ENOV
-2.2%
-2.3%
BLKB
Higher net margin
BLKB
BLKB
116.5% more per $
BLKB
12.4%
-104.1%
ENOV
More free cash flow
BLKB
BLKB
$26.0M more FCF
BLKB
$55.0M
$29.1M
ENOV
Faster 2-yr revenue CAGR
ENOV
ENOV
Annualised
ENOV
9.8%
3.0%
BLKB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BLKB
BLKB
ENOV
ENOV
Revenue
$295.3M
$548.9M
Net Profit
$36.7M
$-571.1M
Gross Margin
58.3%
59.9%
Operating Margin
20.0%
-101.7%
Net Margin
12.4%
-104.1%
Revenue YoY
-2.3%
-2.2%
Net Profit YoY
110.6%
18.8%
EPS (diluted)
$0.75
$-9.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLKB
BLKB
ENOV
ENOV
Q4 25
$295.3M
$548.9M
Q3 25
$281.1M
$564.5M
Q2 25
$282.0M
$558.8M
Q1 25
$269.9M
Q4 24
$302.1M
$561.0M
Q3 24
$286.6M
$505.2M
Q2 24
$287.3M
$525.2M
Q1 24
$278.6M
$516.3M
Net Profit
BLKB
BLKB
ENOV
ENOV
Q4 25
$36.7M
$-571.1M
Q3 25
$47.5M
$-36.7M
Q2 25
$26.5M
$-56.0M
Q1 25
$4.3M
Q4 24
$-346.4M
$-703.2M
Q3 24
$18.3M
$-31.5M
Q2 24
$21.2M
$-18.6M
Q1 24
$7.3M
$-72.0M
Gross Margin
BLKB
BLKB
ENOV
ENOV
Q4 25
58.3%
59.9%
Q3 25
59.6%
59.3%
Q2 25
59.7%
59.5%
Q1 25
57.5%
Q4 24
53.8%
54.8%
Q3 24
54.9%
56.7%
Q2 24
56.0%
55.0%
Q1 24
54.1%
57.7%
Operating Margin
BLKB
BLKB
ENOV
ENOV
Q4 25
20.0%
-101.7%
Q3 25
19.4%
-3.0%
Q2 25
20.3%
-8.4%
Q1 25
7.3%
Q4 24
-121.5%
-118.5%
Q3 24
14.4%
-6.3%
Q2 24
14.4%
-8.4%
Q1 24
4.8%
-6.8%
Net Margin
BLKB
BLKB
ENOV
ENOV
Q4 25
12.4%
-104.1%
Q3 25
16.9%
-6.5%
Q2 25
9.4%
-10.0%
Q1 25
1.6%
Q4 24
-114.6%
-125.4%
Q3 24
6.4%
-6.2%
Q2 24
7.4%
-3.5%
Q1 24
2.6%
-13.9%
EPS (diluted)
BLKB
BLKB
ENOV
ENOV
Q4 25
$0.75
$-9.99
Q3 25
$0.98
$-0.64
Q2 25
$0.55
$-0.98
Q1 25
$0.09
Q4 24
$-6.82
$-12.69
Q3 24
$0.35
$-0.58
Q2 24
$0.41
$-0.34
Q1 24
$0.14
$-1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLKB
BLKB
ENOV
ENOV
Cash + ST InvestmentsLiquidity on hand
$38.9M
$33.6M
Total DebtLower is stronger
$1.1B
$1.4B
Stockholders' EquityBook value
$85.1M
$2.0B
Total Assets
$2.4B
$4.4B
Debt / EquityLower = less leverage
13.06×
0.67×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLKB
BLKB
ENOV
ENOV
Q4 25
$38.9M
$33.6M
Q3 25
$38.3M
$44.1M
Q2 25
$41.6M
$38.5M
Q1 25
$37.2M
Q4 24
$67.6M
$48.2M
Q3 24
$34.6M
$35.4M
Q2 24
$30.4M
$35.0M
Q1 24
$26.4M
$66.3M
Total Debt
BLKB
BLKB
ENOV
ENOV
Q4 25
$1.1B
$1.4B
Q3 25
$1.4B
Q2 25
$1.4B
Q1 25
Q4 24
$1.1B
$1.3B
Q3 24
$1.0B
$1.3B
Q2 24
$1.0B
$1.3B
Q1 24
$1.3B
Stockholders' Equity
BLKB
BLKB
ENOV
ENOV
Q4 25
$85.1M
$2.0B
Q3 25
$108.2M
$2.6B
Q2 25
$72.7M
$2.6B
Q1 25
$17.5M
Q4 24
$126.8M
$2.6B
Q3 24
$544.8M
$3.3B
Q2 24
$577.5M
$3.3B
Q1 24
$534.0M
$3.3B
Total Assets
BLKB
BLKB
ENOV
ENOV
Q4 25
$2.4B
$4.4B
Q3 25
$2.1B
$5.0B
Q2 25
$2.6B
$4.9B
Q1 25
$2.1B
Q4 24
$2.5B
$4.7B
Q3 24
$2.6B
$5.6B
Q2 24
$3.0B
$5.4B
Q1 24
$2.5B
$5.5B
Debt / Equity
BLKB
BLKB
ENOV
ENOV
Q4 25
13.06×
0.67×
Q3 25
0.54×
Q2 25
0.53×
Q1 25
Q4 24
8.50×
0.52×
Q3 24
1.84×
0.40×
Q2 24
1.78×
0.41×
Q1 24
0.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLKB
BLKB
ENOV
ENOV
Operating Cash FlowLast quarter
$58.0M
$82.6M
Free Cash FlowOCF − Capex
$55.0M
$29.1M
FCF MarginFCF / Revenue
18.6%
5.3%
Capex IntensityCapex / Revenue
1.0%
9.7%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters
$257.8M
$22.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLKB
BLKB
ENOV
ENOV
Q4 25
$58.0M
$82.6M
Q3 25
$139.2M
$47.8M
Q2 25
$66.9M
$-1.6M
Q1 25
$1.4M
Q4 24
$73.6M
$88.3M
Q3 24
$104.0M
$53.6M
Q2 24
$53.1M
$7.8M
Q1 24
$65.3M
$-36.2M
Free Cash Flow
BLKB
BLKB
ENOV
ENOV
Q4 25
$55.0M
$29.1M
Q3 25
$135.7M
$3.4M
Q2 25
$66.3M
$-44.9M
Q1 25
$712.0K
Q4 24
$73.4M
$35.1M
Q3 24
$102.9M
$2.4M
Q2 24
$48.0M
$-31.6M
Q1 24
$64.3M
$-73.1M
FCF Margin
BLKB
BLKB
ENOV
ENOV
Q4 25
18.6%
5.3%
Q3 25
48.3%
0.6%
Q2 25
23.5%
-8.0%
Q1 25
0.3%
Q4 24
24.3%
6.3%
Q3 24
35.9%
0.5%
Q2 24
16.7%
-6.0%
Q1 24
23.1%
-14.2%
Capex Intensity
BLKB
BLKB
ENOV
ENOV
Q4 25
1.0%
9.7%
Q3 25
1.2%
7.9%
Q2 25
0.2%
7.7%
Q1 25
0.3%
Q4 24
0.1%
9.5%
Q3 24
0.4%
10.1%
Q2 24
1.8%
7.5%
Q1 24
0.4%
7.2%
Cash Conversion
BLKB
BLKB
ENOV
ENOV
Q4 25
1.58×
Q3 25
2.93×
Q2 25
2.53×
Q1 25
0.32×
Q4 24
Q3 24
5.69×
Q2 24
2.50×
Q1 24
8.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLKB
BLKB

Contractual Recurring$182.7M62%
Transactional Recurring$108.0M37%
One Time Services And Other$4.5M2%

ENOV
ENOV

Reconstructive Segment$258.0M47%
Surgical$129.0M23%
Prevention And Recovery$92.6M17%
Other Prevention And Recovery$71.4M13%

Related Comparisons